NanoViricides News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.04.18	NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today (PR Newswire)
19.03.18	NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin (PR Newswire)
21.02.18	NanoViricides Files Quarterly Report for Period Ending December 31, 2017 (PR Newswire)
06.12.17	Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates (PR Newswire)
20.11.17	NanoViricides Files Quarterly Report for Period Ending September 30, 2017 (PR Newswire)
06.11.17	NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology... (PR Newswire)
26.10.17	Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center (PR Newswire)
17.10.17	NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American... (PR Newswire)
11.09.17	NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017 (PR Newswire)
10.07.17	NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin (PR Newswire)
26.06.17	NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology (PR Newswire)
20.06.17	NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology (PR Newswire)
13.06.17	NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City (PR Newswire)
12.06.17	Global Chatbots Market Demonstrates Worth of 6 Billion USD at 37% of CAGR by 2023 (PR Newswire)
06.06.17	NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies (PR Newswire)
16.05.17	NanoViricides Files Quarterly Report for Period Ending 2017-03-31 (PR Newswire)
26.04.17	NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment... (PR Newswire)
13.02.17	NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company (PR Newswire)
01.12.16	NanoViricides Publishes a Letter from the CEO to Shareholders on its Website (PR Newswire)
11.11.13	NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency (EMA) (Businesswire)
08.07.13	NanoViricides Signs Agreement with Public Health England for Testing of Various NanoViricides Against Specific Viruses of Current Concern (Businesswire)
22.05.12	NanoViricides Files Quarterly Report (Businesswire)
14.05.12	NanoViricides Appoints Mr. Andrew Hahn as Consultant for Design and Construction of Pilot cGMP Production Facility (Businesswire)
07.05.12	NanoViricides Announces Issuance of a Fundamental Patent in the USA (Businesswire)
01.05.12	NanoViricides to Present at the 21st Annual NYBA Meeting in NYC on May 2nd (Businesswire)
02.04.12	NanoViricides Announces Successful Pre-IND Meeting with the US FDA (Businesswire)
05.03.12	NanoViricides Announces US FDA Has Confirmed Pre-IND Meeting Date (Businesswire)
13.02.12	NanoViricides to Present at the 14th Annual BIO-CEO Conference in NYC today (Businesswire)
09.02.12	NanoViricides Completes a $5 Million Raise in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand (Businesswire)
05.12.11	NanoViricides, Inc. Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide™ (Businesswire)
16.11.11	Advaxis Licenses Novel Antigen for Severe Breast Cancer and Other Tumor Types (Businesswire)
16.11.11	NanoViricides Files Quarterly Report (Businesswire)
01.08.11	Cracker Barrel Announces Leadership Transition and Addition to Board of Directors (Businesswire)
22.11.10	Compugen Announces Discovery Platform for New Members of Protein Families with Known Therapeutic Applications (Businesswire)
14.10.10	IBM and ANTs Software to Showcase the IBM DB2 SQL Skin Innovation at Upcoming IBM Information On Demand Conference in Las Vegas, Nevada (Businesswire)
16.08.10	NanoViricides Reports that its Drug Candidates Demonstrated Significant Inhibition of Herpes Virus Infection (Businesswire)
19.07.10	ANTs Software Announces First Acquisition of Sybase to DB2 Migration Technology and Services with Global Financial Services Leader (Businesswire)
08.06.10	WOWIO Acquires DrunkDuck -- The Leading Online Community of Webcomic Readers, Creators and Enthusiasts (Businesswire)
08.06.10	PolyMedix to Review Results from Recent Phase 1B LMWH Reversal Clinical Study with Heptagonist PMX-60056 (Businesswire)
17.05.10	Fuel Tech Awarded Air Pollution Control Orders Totaling $5.1M; Includes Orders from Recently Announced Alliance Agreement (Businesswire)
17.05.10	Shrink Solar's Quantum Dot Technology Achieves 12.6% Optical Efficiency in Published Study (Businesswire)
13.05.10	Arrowhead Reports Fiscal 2010 Second Quarter Financial Results (Businesswire)
26.04.10	Covidien Launches EXALGO™ Extended-Release Tablets (Businesswire)
26.04.10	Arrowhead Announces the Appointment of Former FDA Commissioner and National Cancer Institute Director Dr. Andrew von Eschenbach to Its Board of Advisors (Businesswire)
26.04.10	Bruker Receives Contract from National Institute of Standards and Technology (NIST) for N8 TITANOS Large Sample Atomic Force Microscope (AFM) System (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu NanoViricides Inc

Aktien Top/Flop

Meistgelesene Nachrichten